foscarnet
Trade name: foscavir
Approved
Sep 27, 1991
Foscarnet is an antiviral agent. Foscarnet shows activity against human herpesviruses and HIV. Foscarnet is used for treating eye problems caused by CMV in people with AIDS. It is also used to treat a type of HSV that cannot be treated by another medicine in people with a weak immune system. FOSCAVIR is the brand name for foscarnet sodium. FOSCAVIR is an organic analogue of inorganic pyrophosphate that inhibits replication of herpesviruses in vitro including cytomegalovirus (CMV) and herpes simplex virus types 1 and 2 (HSV-1 and HSV-2). FOSCAVIR exerts its antiviral activity by a selective inhibition at the pyrophosphate binding site on virusspecific DNA polymerases at concentrations that do not affect cellular DNA polymerases. FOSCAVIR does not require activation (phosphorylation) by thymidine kinase or other kinases and therefore is active in vitro against HSV TK deficient mutants and CMV UL97 mutants. Thus, HSV strains resistant to acyclovir or CMV strains resistant to ganciclovir may be sensitive to FOSCAVIR. — NCATS
Clinical trial activity
29 trials · 31 clinical orgs · 8 marketing orgs
Earliest trial started Mar 1, 1990 (NCT00000136)
Timeline
1990s
- Jan 1, 1990
Earliest Phase 3 Sponsor(trial)
- Sep 27, 1991
Clinigene International Ltd — Earliest FDA Approval
- Sep 27, 1991
Clinigene International Ltd — NDA Organization
- Sep 27, 1991
Clinigene International Ltd — NDA Secondary Org
- Jan 1, 1999
Earliest Phase 1 Sponsor(trial)
- Jan 1, 1999
Earliest Phase 2 Sponsor(trial)
2000s
- May 31, 2005
Hospira — Marketing Organization
2020s
- Jan 29, 2021
Fresenius — Marketing Organization
- Apr 21, 2021
Gland Pharma Ltd — Marketing Organization
- Apr 21, 2021
Fosun — Marketing Organization
- Jun 5, 2023
Avet Lifesciences — Marketing Organization
- Nov 29, 2023
Beijing Pearl Biotechnology Limited Liability Company — Marketing Organization
- Mar 1, 2024
Amneal Pharmaceuticals — Marketing Organization
Indications
Studied for
- Acne Vulgaris · Phase 2
- Acquired Immunodeficiency Syndrome · Phase 3
- Brain Diseases · Phase 1
- Cytomegalovirus Infections · Phase 4
- Cytomegalovirus Retinitis · Phase 4
- Gastrointestinal Diseases · Phase 3
- Graft vs Host Disease · Phase 2
- Hematologic Diseases · Phase 4
- Herpes Simplex · Phase 3
- Herpes Zoster · Phase 4
- HIV Infections · Phase 4
- Hypocalcemia · Phase 4
- Radiculopathy · Phase 1
Mechanism of action
- Human herpesvirus 1 DNA polymeraseINHIBITOR
Human herpesvirus 1 DNA polymerase inhibitor
Approval history
- approvedPriority reviewSep 27, 1991
Chemistry & pharmacology
SMILES
O=C(O)P(=O)(O)O- Mol. weight
- 126 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Prescription Only
Oral
No
Parenteral
Yes
Topical
No
Sources
- ChEMBLCHEMBL666 ↗
- WikipediaFoscarnet ↗
- NCATS364P9RVW4X ↗
- ChEMBLCHEMBL754 ↗
Also known as
- carboxyphosphonic acid
- carboxyphosphonic acid
- dihydroxyphosphinecarboxylic acid oxide
- dihydroxyphosphinecarboxylic acid oxide
- ehb-776
- ehb-776
- foscarmet
- foscarmet
- foscarnet
- foscarnet
- foscarnet
- foscarnet
- foscarnet
- foscarnet
- foscarnet
- foscarnet
- foscarnet sodium
- foscarnet sodium
- foscarnet sodium
- foscarnet sodium
- foscarnet sodium hydrate
- foscavir
- foscavir
- foscavir
- foscavir
- foscavir
- foscavir
- foscavir
- phosphonocarboxylic acid
- phosphonoformate
- phosphonoformate
- phosphonoformic acid
- phosphonoformic acid
- phosphonoformic acid
- phosphonomethanoic acid
- phosphonomethanoic acid
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03073967 | Phase 2 | May 8, 2017 | AiCuris Anti-infective Cures GmbH, Medpace, Inc. |
| NCT02931539 | Phase 3 | Dec 1, 2016 | Shire |
| NCT03004261 | Phase 4 | Nov 1, 2016 | Jiao Tong University, Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China |
| NCT02151240 | Phase 4 | May 1, 2014 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd, Peking University |
| NCT01199562 | N/A | Dec 1, 2010 | City of Hope National Medical Center, National Cancer Institute (NCI) |
| NCT00986557 | Phase 2 | Sep 1, 2009 | University of Birmingham |
| NCT00000766 | Phase 2 | Nov 2, 1999 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00000856 | Phase 1 | Nov 2, 1999 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00000964 | Phase 1 | Nov 2, 1999 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00000970 | Phase 1 | Nov 2, 1999 | Astra, National Institute of Allergy and Infectious Diseases (NIAID), Roche |
| NCT00000985 | Phase 3 | Nov 2, 1999 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00001002 | Phase 1 | Nov 2, 1999 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00001061 | Phase 2 | Nov 2, 1999 | Facet Biotech, National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00002039 | N/A | Nov 2, 1999 | Astra |
| NCT00002125 | Phase 4 | Nov 2, 1999 | Astra |
| NCT00002144 | Phase 1 | Nov 2, 1999 | Astra |
| NCT00002145 | Phase 3 | Nov 2, 1999 | Astra |
| NCT00002146 | Phase 4 | Nov 2, 1999 | Astra |
| NCT00002272 | N/A | Nov 2, 1999 | Astra |
| NCT00002301 | N/A | Nov 2, 1999 | Astra |
Organizations
Research & Development (31)
Marketing (9)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Amneal Pharmaceuticals | For profit | MKTG | Mar 1, 2024 |
| Avet Lifesciences | For profit | MKTG | Jun 5, 2023 |
| Beijing Pearl Biotechnology Limited Liability Company | Government | MKTG | Nov 29, 2023 |
| Clinigene International Ltd | For profit | NDA | Sep 27, 1991 |
| Clinigene International Ltd | For profit | NDA2 | Sep 27, 1991 |
| Fosun | For profit | MKTG | Apr 21, 2021 |
| Fresenius | For profit | MKTG | Jan 29, 2021 |
| Gland Pharma Ltd | For profit | MKTG | Apr 21, 2021 |
| Hospira | For profit | MKTG | May 31, 2005 |